CNS Outcomes in ALK Fusion Positive NSCLC Patients with BM Who Received Alectinib with or without Local Therapy

被引：0
|
作者：
Miao, E. [1 ]
Lebow, E. S. [2 ]
Eichholz, J. [3 ]
Flynn, J.
Zhang, Z. [3 ,4 ]
Hubbeling, H. G.
Beal, K.
Moss, N. S. [5 ]
Yu, K. [3 ]
Yang, J. T. [3 ]
Kelly, D. W. [3 ]
Gomez, D. R. [2 ]
Rimner, A. [2 ]
Drilon, A. [5 ]
Imber, B. S. [6 ]
Pike, L. R. G. [3 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Brain Metastasis Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2131
引用
收藏
页码：E59 / E60
页数：2
相关论文
共 50 条
  • [31] A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy
    Bos, M.
    Gardizi, M.
    Heukamp, L. C.
    Schildhaus, H. -U.
    Merkelbach-Bruse, S.
    Nogova, L.
    Scheffler, M.
    Serke, M.
    Schulz, H.
    Krueger, S.
    Bruemmendorf, T. H.
    Panse, J.
    Schmitz, S.
    Gerigk, U.
    Randerath, W. J.
    Ko, Y. D.
    Kambartel, K.
    Huenerlituerkoglu, A. -N.
    Buettner, R.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 91 - 91
  • [32] Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
    Cheung, Justin M.
    Kang, Jiyoon
    Yeap, Beow Y.
    Peterson, Jennifer L.
    Do, Andrew
    Gainor, Justin F.
    Digumarthy, Subba R.
    Lin, Jessica J.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (03):
  • [33] ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK plus ) NSCLC Patients in the US Community Oncology Setting
    Waterhouse, D.
    Espirito, J.
    Chioda, M.
    Baidoo, B.
    Mardekian, J.
    Robert, N.
    Masters, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S560
  • [34] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
    Chang, Gee-Chen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Su, Kang-Yi
    Yu, Sung-Liang
    Tseng, Jeng-Sen
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [35] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
    Gee-Chen Chang
    Tsung-Ying Yang
    Kun-Chieh Chen
    Kuo-Hsuan Hsu
    Yen-Hsiang Huang
    Kang-Yi Su
    Sung-Liang Yu
    Jeng-Sen Tseng
    Scientific Reports, 10
  • [36] Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S412
  • [37] Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
    Bernabe-Caro, R.
    Garcia-Campelo, R.
    Garrido, P.
    Palmero, R.
    Artal, A.
    Bayona, C.
    Rodriguez-Abreu, D.
    Lopez-Brea, M.
    Paredes, A.
    Vicente, D.
    Torres, J. M. Sanchez
    Majem, M.
    Diz, P.
    Gordo, R.
    Coca, M.
    de Castro, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S465 - S466
  • [38] Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK plus NSCLC Patients (Pts)
    Nishio, M.
    Kiura, K.
    Seto, T.
    Nakagawa, K.
    Maemondo, M.
    Inoue, A.
    Hida, T.
    Yoshioka, H.
    Harada, M.
    Ohe, Y.
    Nogami, N.
    Murakami, H.
    Takeuchi, K.
    Inamura, S.
    Kuriki, H.
    Shimada, T.
    Tamura, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1757 - S1757
  • [39] Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
    Nishio, Makoto
    Yoshida, Tatsuya
    Kumagai, Toru
    Hida, Toyoaki
    Toyozawa, Ryo
    Shimokawaji, Tadasuke
    Goto, Koichi
    Nakagawa, Kazuhiko
    Ohe, Yuichiro
    Seto, Takashi
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 452 - 463
  • [40] Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)
    To, B.
    Farid, S.
    Zhao, S.
    Li, M.
    Amirmokhtari, N.
    Wei, L.
    Memmott, R.
    Alahmadi, A.
    He, K.
    Kaufman, J.
    Roof, L.
    Shields, P.
    Carbone, D.
    Otterson, G.
    Presley, C.
    Owen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S644 - S645
12345